Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment

Abstract

Hao Wang1,2, Sha Zhao1,2, Xiaoshen Zhang1,2, Keyi Jia1,2, Juan Deng1,2, Caicun Zhou1, Yayi He1 1Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, People’s Republic of China; 2Medical School, Tongji University, Shanghai 200433, People’s Republic of ChinaCorrespondence: Caicun Zhou; Yayi HeDepartment of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, No 507 Zhengmin Road, Shanghai 200433, People’s Republic of ChinaTel [phone]; [phone]Email [email protected]; [email protected]: Lung cancer is one of the commonest cancers in the world. More than 70% of lung cancer patients are diagnosed with non-small cell lung cancer (NSCLC). Major histocompatibility complex class II (MHC class II), an important component in antigen presenting process, usually expresses on professional antigen presenting cells (APCs), and it can be induced by interferon-γ (IFN-γ). MHC class II can be expressed by NSCLC cells. In NSCLC patients, the expression of MHC class II can be correlated with the outcome of anti-programmed death-1 (anti-PD-1) therapy. This review summarizes MHC class II expression in NSCLC and the correlation between MHC class II and NSCLC diagnosis, prognosis and therapy.Keywords: major histocompatibility complex class II, non-small cell lung cancer, immune therapy

Keywords

• major histocompatibility complex class II
• non-small cell lung cancer
• immune therapy